CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

CURIS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.38−0.03 (-6.26%)

Close on Oct 19, 2026

Market cap: $815.06K
P/E (TTM): –
Dividend yield: –

CURIS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	9.44	11	10	10	11	11	10	10	9.90	7.53	7.88	9.84	15	17	15	16	8.59
Research & Development	28	39	39	43	35	23	22	24	45	18	27	14	13	15	14	11	9.93
General & Administrative	14	17	19	20	17	12	12	15	14	16	13	12	11	10	8.27	10	8.70
Total Costs & Expenses	42	55	58	63	53	36	34	40	60	66	64	26	24	36	22	22	19
Operating Income	-5.71	-45	-48	-53	-42	-25	-24	-29	-50	-58	-56	-16	-9.42	-19	-7.20	-5.64	-10
Interest Expense	–	–	–	–	0	0	0.79	3.93	3.97	2.78	3.33	3.75	3.84	0.20	–	–	–
Interest & Investment Income	0.32	1.77	2.94	1.12	0.21	0.06	0.61	0.68	0.51	0.41	0.28	0.17	0.16	0.15	0.10	0.14	0.22
Other Non-Operating Income	-1.87	1.15	0.92	-3.65	-3.37	-5.01	-7.79	-3.24	-3.56	-2.37	-2.50	-2.87	-2.91	2.20	-2.66	1.20	0.22
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	–
Gain (Loss) on Sale of Assets	27	0	–	–	0	-0.02	-0.03	-0.01	0	0	0.02	0.00	–	–	0.08	0.10	–
Income Tax Expense	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-7.58	-43	-47	-57	-45	-30	-32	-33	-53	-60	-59	-19	-12	-16	-9.86	-4.44	-9.82
EPS (Basic)(per share)	-11.60	-137.60	-179.20	-242.80	200.00	-244.00	-388.00	-392.00	-716.00	-900.00	-960.00	-440.00	-300.00	-420.00	-260.00	-120.00	-300.00
EPS (Diluted)(per share)	-11.60	-137.60	-179.20	-242.80	200.00	-244.00	-388.00	-392.00	-716.00	-900.00	-960.00	-440.00	-300.00	-420.00	-260.00	-120.00	-300.00
Shares Outstanding (Basic, Weighted)(shares)	0.66	0.32	0.26	0.23	0.23	0.12	0.08	0.08	0.07	0.07	0.06	0.04	0.04	0.04	0.04	0.04	–
Shares Outstanding (Diluted, Weighted)(shares)	0.66	0.32	0.26	0.23	0.23	0.12	0.08	0.08	0.07	0.07	0.06	0.04	0.04	0.04	0.04	0.04	–
EBITDA	-5.54	-44	-48	-53	-42	-25	-24	-29	-50	-58	-56	-16	-9.27	-18	-7.10	-4.95	-9.29

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -203.2%
Net margin: -490.3%
Return on equity, FY2025: 2829.1%

Financial strength

Current ratio: 0.49
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 37.1%

Valuation

P/E ratio: –
Price to sales: 0.19
Price to book: 0.17
Dividend yield: –